The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients.
Jung-min Lee
No relevant relationships to disclose
Christina M. Annunziata
No relevant relationships to disclose
John L. Hays
No relevant relationships to disclose
Peter L. Choyke
No relevant relationships to disclose
Liang Cao
No relevant relationships to disclose
Minshu Yu
No relevant relationships to disclose
Nilofer Saba Azad
No relevant relationships to disclose
Nicole D. Houston
No relevant relationships to disclose
Lori M. Minasian
No relevant relationships to disclose
Nicolas Gordon
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Elise C. Kohn
No relevant relationships to disclose